Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors

Exclusion Criteria

• •1. Patients with ovarian tumors with low malignant potential (i.e. borderline tumors);
• •2. Patients with evidence of abdominal free air not explained by paracentesis or recent surgical procedure (prior, current or planned treatment).
• •3. Prior treatment of any adoptive T cell therapy.
• •4. Current or recent treatment (within the 14-day period prior to Day 0) with any immune suppressive drug
• •5. Minor surgical procedures within 2 days prior to Day 0 (including central venous access device placement for chemotherapy administration, tumor biopsies, needle aspirations).
• •6. Pregnant or lactating females.
• •7. Inadequate bone marrow function with
• •* absolute neutrophil count \< 1,000/mm\^3;
• •* platelet count \< 100,000/mm\^3;
• •* Hb \< 9 g/dL.
• •8. Inadequate liver and renal function with
• •* serum (total) bilirubin \> 1.5 x ULN;
• •* AST \& ALT \> 2.5 x ULN (\> 5 x ULN in patients with liver metastases);
• •* alkaline phosphatase \> 2.5 x ULN;
• •* serum creatinine \>2.0 mg/dl (\> 177 μmol/L);
• •* urine dipstick for protein uria should be \< 2+. Patients with ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo 24 hour urine collection and must demonstrate \< 1 g of protein/24 hr.
• •9. Serious active infection requiring i.v. antibiotics
• •10. Subject infected with HCV (HCV antibody positive), or HIV (HIV antibody positive),Treponema pallidum antibody positive or TB culture positive.